Results 61 to 70 of about 164,355 (372)

Single-domain antibodies and their formatting to combat viral infections [PDF]

, 2018
Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies, De Vlieger, Dorien, Rossey, Iebe, Saelens, Xavier, Schepens, Bert   +4 more
core   +2 more sources

The recent landscape of RSV vaccine research

Therapeutic Advances in Vaccines and Immunotherapy
Respiratory syncytial virus (RSV) causes a significant burden of acute respiratory illness across all ages, particularly for infants and older adults. Infants, especially those born prematurely or with underlying health conditions, face a high risk of ...
Karen J Kelleher, Nadisha Subramaniam, S. Drysdale   +2 more
semanticscholar   +1 more source

Multiple Respiratory Syncytial Virus (RSV) Strains Infecting HEp-2 and A549 Cells Reveal Cell Line-Dependent Differences in Resistance to RSV Infection

Journal of Virology, 2022
Infection with the respiratory syncytial virus (RSV) early in life is essentially guaranteed and can lead to severe disease. Most RSV studies have involved either of two historic RSV/A strains infecting one of two cell lines, HEp-2 or A549 cells ...
Anubama Rajan, Felipe-Andrés Piedra, Letisha Aideyan, Trevor McBride, M. Robertson, Hannah L. Johnson, G. Aloisio, D. Henke, C. Coarfa, F. Stossi, Vipin K. Menon, H. Doddapaneni, D. Muzny, S. J. Javornik Cregeen, K. Hoffman, J. Petrosino, R. Gibbs, V. Avadhanula, P. Piedra   +18 more
semanticscholar   +1 more source

Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025

Eurosurveillance
We measured effectiveness of nirsevimab against laboratory-confirmed respiratory syncytial virus (RSV) infection in a test-negative case-control study among children aged 
VEBIS hospital network RSV IE group
doaj   +1 more source

Epidemic dynamics of respiratory syncytial virus in current and future climates. [PDF]

, 2019
A key question for infectious disease dynamics is the impact of the climate on future burden. Here, we evaluate the climate drivers of respiratory syncytial virus (RSV), an important determinant of disease in young children.
Baker, Rachel E, Grenfell, Bryan T, Mahmud, Ayesha S, Metcalf, C Jessica E, Pitzer, Virginia E, Vecchi, Gabriel A, Viboud, Cecile, Wagner, Caroline E, Yang, Wenchang   +8 more
core   +2 more sources

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study

Journal of Infectious Diseases, 2021
Background Respiratory syncytial virus (RSV) is a significant cause of severe lower respiratory tract disease in children and older adults, but has no approved vaccine.
J. Sadoff, E. de Paepe, J. DeVincenzo, E. Gymnopoulou, J. Menten, Bryan Murray, A. R. Bastian, A. Vandebosch, W. Haazen, N. Noulin, C. Comeaux, E. Heijnen, Kingsley Eze, A. Gilbert, Rob Lambkin-Williams, H. Schuitemaker, Benoît Callendret   +16 more
semanticscholar   +1 more source

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons

Clinical Infectious Diseases
Background The adjuvanted RSV prefusion F protein–based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-years-olds over 1 RSV season.
Michael G. Ison, A. Papi, Eugene Athan, Robert G. Feldman, Joanne M Langley, Dong-Gun Lee, I. Leroux-Roels, F. Martinón-Torres, Tino F. Schwarz, Richard N van Zyl-Smit, Céline Verheust, N. Dezutter, Olivier Gruselle, L. Fissette, M. David, L. Kostanyan, V. Hulstrøm, Aurélie Olivier, M. Van der Wielen, Dominique Descamps   +19 more
semanticscholar   +1 more source

The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries

Open Forum Infectious Diseases, 2021
Background Respiratory syncytial virus (RSV) is one of the leading causes of acute respiratory tract infections. To optimize control strategies, a better understanding of the global epidemiology of RSV is critical.
Lisa Staadegaard, S. Caini, S. Wangchuk, B. Thapa, W. A. F. de Almeida, Felipe Cotrim de Carvalho, R. Njouom, R. Fasce, P. Bustos, J. Kynčl, L. Nováková, A. Caicedo, Domenica Joseth de Mora Coloma, A. Meijer, M. Hooiveld, Sue Huang, T. Wood, R. Guiomar, A. Rodrigues, D. Danilenko, K. Stolyarov, V. Lee, L. Ang, C. Cohen, J. Moyes, A. Larrauri, C. Delgado-Sanz, M. Le, P. M. V. Hoang, C. Demont, M. Bangert, J. V. van Summeren, M. Dückers, J. Paget   +33 more
semanticscholar   +1 more source

Agapeic Theism: Personifying Evidence and Moral Struggle [PDF]

, 2010
The epistemology of monotheism offered by philosophers has given inadequate attention to the kind of foundational evidence to be expected of a personal God whose moral character is ’agapeic’, or perfectly loving, toward all other agents.
Moser, Paul K.
core   +1 more source

Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants 
Corinna Ernst, D. Bejko, Leo Gaasch, Emilie Hannelas, Isaline Kahn, Charlotte Pierron, Nesrine Del Lero, Claude Schalbar, Elsa Do Carmo, Michel Kohnen, Emmanuelle Andlauer, Pauline Hublart, S. Masi, Isabel de la Fuente Garcia, A. Vergison, Joël Mossong   +15 more
semanticscholar   +1 more source